natgillin/translations-raw huggingface dataset:
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. 
Molimo Vas obavijestite svog liječnika ili ljekarnika ukoliko uzimate ili ste nedavno uzimali bilo koje druge lijekove, uključujući lijekove koji se mogu dobiti bez recepta.
These symptoms resolved once the dose was reduced. 
Ovi su simptomi prestali nakon smanjenja doze.
Please consult your doctor for advice if you are pregnant or planning to become pregnant. 
Molimo Vas da se posavjetujete s Vašim liječnikom ukoliko ste trudni ili planirate trudnoću.
Read all of this leaflet carefully before you start taking this medicine. 
Pažljivo pročitajte cijelu uputu prije nego počnete uzimati ovaj lijek.
Based on clinical experience, the treatment may be started as early as the first day of life. 
Na temelju kliničkog iskustva, liječenje se smije započeti već prvi dan života.
This disorder persists during the entire life of the affected patient and therefore the need for this treatment is lifelong. 
Ovaj poremećaj traje tijekom čitavog života bolesnika te je stoga potreba za ovim liječenjem doživotna.
Their range was consistent with those measured in healthy adults, even in newborn infants. 
Njen raspon bio je u skladu s onim izmjerenim kod zdravih odraslih osoba, čak i kod novorođenčadi.
No specific interaction studies have been performed. 
Nisu provedena specifična ispitivanja interakcija.
Always take Carbaglu exactly as your doctor has instructed you. 
Uvijek uzimajte Carbaglu točno kako Vam je propisao Vaš liječnik.
When the treatment was instituted before any permanent brain damage, patients exhibited normal growth and psychomotor development. 
Kada se liječenje uvede prije trajnog oštećenja mozga, bolesnici pokazuju normalan rast i psihomotorni razvoj.
36 months After first opening of the tablet container: 3 months 
36 mjeseci Nakon prvog otvaranja spremnika s tabletama: 3 mjeseca
This leaflet was last approved on 
Uputa je zadnji puta odobrena u
Patients suffering from one of these disorders need treatment during the hyperammonaemia crisis. 
Bolesnici koji imaju jedan od ovih poremećaja trebaju se liječiti tijekom hiperamonijemične krize.
Date of first authorisation: 24 January 2003 Date of renewal: 20 May 2008 
Datum obnove: 20. svibanj 2008.
EU/1/02/246/001 (15 dispersible tablets) EU/1/02/246/002 (60 dispersible tablets) EU/1/02/246/003 (5 dispersible tablets) 
EU/1/02/246/001 (15 tableta za oralnu suspenziju) EU/1/02/246/002 (60 tableta za oralnu suspenziju) EU/1/02/246/003 (5 tableta za oralnu suspenziju)
In order to follow-up your condition and your treatment, your doctor may examine your liver, your kidneys, your heart and your blood on a regular basis. 
Radi praćenja Vašeg stanja i liječenja, liječnik može redovito pregledavati Vašu jetru, bubrege, srce te krv.
Protein binding has not been determined. 
Vezanje za proteine nije utvrđeno.
Based on pharmacokinetic data and clinical experience, it is recommended to divide the total daily dose into two to four doses to be given before meals or feedings. 
Na temelju farmakokinetičkih podataka i kliničkog iskustva preporučuje se podijeliti ukupnu dnevnu dozu na dvije do četiri doze dane prije obroka ili hranjenja.
2.2 Qualitative and quantitative composition For a full list of excipients, see section 6.1 
2.2 Kvalitativan i kvantitativan sastav Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
The breaking of the tablets in halves allows most of the required posology adjustments. 
Lomljenje tableta na pola omogućuje većinu potrebnih prilagodbi doziranja.
Animal studies have revealed minimal developmental toxicity (see section 5.3). 
Studije na životinjama pokazale su minimalnu razvojnu toksičnost (vidjeti dio 5.3).
Occasionally, the use of quarter tablets may also be useful to adjust the posology prescribed by the physician. 
Povremeno, primjena četvrtina tableta može također biti korisna da bi se prilagodilo doziranje propisano od strane liječnika.
Diffusion into erythrocytes is non existent. 
Nema difuzije u eritrocite.
What Carbaglu is and what it is used for Before you take Carbaglu How to take Carbaglu Possible side effects 5 How to store Carbaglu Further information 
Što je Carbaglu i za što se koristi Prije nego počnete uzimati Carbaglu Kako uzimati Carbaglu Moguće nuspojave Kako čuvati Carbaglu Dodatne informacije
Like all medicines, Carbaglu can have side effects, although not everybody gets them. 
Kao i svi drugi lijekovi, Carbaglu može uzrokovati nuspojave iako se neće javiti kod svakoga.
Do not store above 30C. 
Ne čuvati na temperaturi iznad 30°C.
Do not take Carbaglu if you are hypersensitive (allergic) to carglumic acid or any of the other ingredients of Carbaglu. 
Nemojte uzimati Carbaglu ako ste preosjetljivi (alergični) na karglumatnu kiselinu ili bilo koji drugi sastojak lijeka Carbaglu.
Pharmacotherapeutic group: Amino acids and derivatives; ATC code: A16AA05 
Farmakoterapijska skupina: Aminokiseline i derivati; ATK oznaka: A16AA05
If you take more Carbaglu than you should Ask your doctor or pharmacist for advice. 
Ako uzmete više lijeka Carbaglu nego što ste trebali Pitajte svog liječnika ili ljekarnika za savjet.
• Common: increased sweating 
• Često: pojačano znojenje
The tablets are white and elongated with three score marks and engraved on one side. 
Tablete su bijele i duguljaste s tri zareza i urezane s jedne strane.
Other studies have been conducted in rats under different experimental conditions leading to increased ammonia availability (starvation, protein-free or high-protein diet). 
Druge su studije provedene na štakorima pod različitima eksperimentalnim okolnostima koje dovode do povećane raspoloživosti amonijaka (gladovanje, dijeta bez proteina ili dijeta s visokom razinom proteina).
Carbaglu can help eliminating excessive ammonia plasma levels (elevated ammonia level in the blood). 
Carbaglu može pomoći u uklanjanju prekomjernih razina amonijaka u plazmi (povišene razine amonijaka u krvi).
Write the date of opening on the tablet container. 
Zapišite datum otvaranja na spremnik tableta.
The maternal systemic exposures after 500 and 2000 mg/kg/day were twenty five times and seventy times the expected human exposure. 
Sistemska izloženost ženki nakon 500 i 2000 mg/kg/dan bila je dvadeset pet puta te sedamdeset puta veća od očekivane izloženosti kod ljudi.
Caution should be exercised when prescribing to pregnant women. 
Potreban je oprez prilikom primjene kod trudnica.
Whatever the daily dose, they were slowly declining over 15 hours to levels around 100 ng/ml. 
Bez obzira na dnevnu dozu, ona se polako spuštala kroz 15 sati do razine od oko 100 ng/ml.
It is suggested that depending on its activity, the intestinal bacterial flora may contribute to the initiation of the degradation process, thus leading to a variable extent of metabolism of the molecule. 
Predloženo je da, ovisno o njenoj aktivnosti, crijevna bakterijska flora može doprinijeti započinjanju procesa razgradnje, dovodeći na taj način do promjenjivog stupnja metabolizma molekule.
No adverse effects have been observed on male or female fertility. 
Nisu zabilježeni štetni učinci na plodnost mužjaka ili ženki.
The tablets must be dispersed in a minimum of 5 to 10 ml of water and taken immediately. 
Tablete treba otopiti u najmanje 5 do 10 ml vode i odmah popiti.
Uncommon: bradycardia 
Manje često: bradikardija
The effects of Carbaglu on pregnancy and the unborn child are not known. 
Nisu poznati učinci lijeka Carbaglu na trudnoću i nerođeno dijete.
Safety pharmacology studies have shown that Carbaglu administered orally at doses of 250, 500, 1000 mg/kg had no statistically significant effect on respiration, central nervous system and cardiovascular system. 
Studije o farmakološkoj sigurnosti pokazale su da peroralna primjena Carbaglu u dozama od 250, 500, 1000 mg/kg nije imala statistički značajan učinak na disanje, središnji živčani sustav i kardiovaskularni sustav.
Your doctor will determine the dose suitable to you in order to maintain normal ammonia levels in your blood. 
Vaš liječnik će odrediti dozu prikladnu za Vas kako bi se održale normalne količine amonijaka u Vašoj krvi.
Patients with this rare disorder are not able to eliminate nitrogen waste, which builds up after eating protein. 
Bolesnici s ovim rijetkim poremećajem ne mogu odstraniti ostatni dušik koji se nagomilava nakon proteinskog obroka.
Do not take Carbaglu: 
Nemojte uzimati Carbaglu:
Ammonia is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma. 
Amonijak je posebno toksičan za mozak te dovodi, u teškim slučajevima, do poremećaja svijesti i kome.
Carbaglu should ONLY be administered by mouth or via a feeding tube into the stomach (using a syringe, if necessary). 
Carbaglu se smije primijeniti SAMO kroz usta ili putem cijevi za hranjenje u trbuh (koristeći štrcaljku, ako je potrebno).
• Uncommon: bradycardia (decreased frequency of the heart), diarrhoea, fever, increased transaminases, vomiting 
• Manje često: bradikardija (smanjena frekvencija srca), proljev, vrućica, porast vrijednosti transaminaza, povraćanje
Carbaglu must be taken orally before meals or feedings. 
Carbaglu se mora uzimati na usta prije obroka ili hranjenja.
Frequencies are defined as: very common (≥ 1/10), common (≥1/100 to 1/10), uncommon (≥1/1,000 to 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Učestalosti su definirane kao: vrlo često (≥1/10), često (≥1/100 i 1/10), manje često (≥1/1000 i 1/100), rijetko (≥1/10000 i <1/1000), vrlo rijetko (<1/10000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Detaljne informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu.
If you stop taking Carbaglu Do not stop Carbaglu without informing your doctor. 
Nemojte prestati uzimati Carbaglu bez informiranja svojeg liječnika.
Common: increased sweating Not known: rash 
Često: pojačano znojenje Nepoznato: osip
Carbaglu showed no significant mutagenic activity in a battery of genotoxicity tests performed in vitro (Ames test, human lymphocyte metaphase analysis) and in vivo (micronucleus test in rat). 
Carbaglu nije pokazao značajnu mutagenu aktivnost u skupini genotoksičnih testova provedenih in vitro (Amesov test, analiza metafaze ljudskih limfocita) te in vivo (mikronukleus test na štakoru).
Store in a refrigerator (2C - 8C) 
Čuvati u hladnjaku (2°C - 8°C)
As very few data on the safety of carglumic acid are available, systematic surveillance of liver, renal, cardiac functions and haematological parameters is recommended. 
Kako je dostupno vrlo malo podataka o sigurnosti karglumatne kiseline, preporučuje se sistematsko praćenje jetrene, bubrežne i srčane funkcije te hematoloških parametara.
In one patient treated with carglumic acid, where the dose was increased up to 750 mg/kg/day, symptoms of intoxication occurred which can be characterised as a sympathomimetic reaction: tachycardia, profuse sweating, increased bronchial secretion, increased body temperature and restlessness. 
Kod jednog bolesnika liječenog karglumatnom kiselinom, kod kojeg je doza povišena do 750 mg/kg/dan, pojavili su se simptomi intoksikacije koji se mogu opisati kao simpatomimetička reakcija: tahikardija, obilno znojenje, povećana bronhalna sekrecija, povišena tjelesna temperatura i nemir.
Taking Carbaglu with food and drink 
Uzimanje Carbaglu s hranom i tekućinom
The pharmacokinetics of carglumic acid has been studied in healthy male volunteers using both radiolabelled and unlabelled product. 
Farmakokinetika karglumatne kiseline proučavana je na zdravim muškim dobrovoljcima pomoću radioaktivno označenog i neoznačenog lijeka.
Carbaglu is indicated in treatment of 
Carbaglu je indiciran za liječenje:
At that dose-level, in 12 volunteers given Carbaglu tablets, plasma concentration peaked at 2.6 µg/ml (median; range 1.8-4.8) after 3 hours (median; range 2-4). 
Pri tim dozama, kod 12 dobrovoljaca koji su dobivali Carbaglu tablete, vršna plazmatska koncentracija bila je 2,6 μg/ml (medijan; raspon 1,8-4,8) nakon 3 sata (medijan; raspon 2
In rats and rabbits no evidence has been seen of embryotoxicity, foetotoxicity or teratogenicity up to maternotoxic doses leading to fifty times exposure as compared to humans in rats and seven times in rabbits. 
Kod štakora i kunića nije bilo dokaza embriotoksičnosti, fetotoksičnosti ili teratogenosti sve do doza toksičnih za majku kod pedeset puta veće izloženosti kod štakora u usporedbi s ljudima te sedam puta kod kunića.
Nevertheless, as carglumic acid has been shown to be present in the milk of lactating rats with potential toxic effects for their fed pups, you should not breast feed your baby if you are taking Carbaglu. 
Međutim, kako se pokazalo da se karglumatna kiselina nalazi u mlijeku ženki štakora tijekom laktaciji te može imati toksične učinke na mladunčad koju doje, ne smijete dojiti svoje dijete ukoliko uzimate Carbaglu.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 
Ako se bilo koja nuspojava pogorša ili ako primijetite bilo koju nuspojavu koja nije navedena u ovoj uputi, molimo obavijestite svog liječnika ili ljekarnika.
The end product of carglumic acid metabolism is carbon dioxide, which is eliminated through the lungs. 
Završni produkt metabolizma karglumatne kiseline je ugljični dioksid koji se odstranjuje plućima.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/. 
Detaljne informacije o ovom lijeku dostupne su na webstranici Europske agencije za lijekove (EMA) http://www.ema.europa.eu/.
Hypersensitivity to the active substance or to any of the excipients. 
Preosjetljivost na djelatnu tvar ili bilo koju od pomoćnih tvari.
Single doses of carglumic acid up to 2800 mg/kg orally and 239 mg/kg intravenously did not induce any mortality or abnormal clinical signs in adult rats. 
Pojedinačne doze karglumatne kiseline do 2800 mg/kg oralno te 239 mg/kg intravenski nisu dovele do mortaliteta ili abnormalnih kliničkih znakova kod odraslih štakora.
Your doctor will evaluate your individual responsiveness to carglumic acid before initiating any long term treatment. 
Liječnik će ispitati Vaš individualni odgovor na karglumatnu kiselinu prije započinjanja dugotrajnog liječenja.
What Carbaglu contains - The active substance is carglumic acid. 
Što Carbaglu sadrži - Djelatna tvar je karglumatna kiselina.
Carbaglu is presented in a plastic container of 5, 15 and 60 tablets which is closed with a child resistant cap. 
Carbaglu dolazi u plastičnom spremniku od 5, 15 i 60 tableta koji je zatvoren poklopcem sa zaštitom za djecu.
Although it is not known whether carglumic acid is secreted into human milk, it has been shown to be present in the milk of lactating rats (see section 5.3). 
Iako nije poznato izlučuje li se karglumatna kiselina u majčinom mlijeku ljudi, pokazano je da se nalazi u mlijeku štakorica tijekom laktacije (vidjeti dio 5.3).
The excretion of carglumic acid into breast milk has not been studied in women. 
Izlučivanje karglumatne kiseline u majčino mlijeko nije proučeno kod žena.
Carglumic acid responsiveness test It is recommended to test individual responsiveness to carglumic acid before initiating any long term treatment. 
Test odgovora na karglumatnu kiselinu Preporučuje se testirati individualni odgovor na karglumatnu kiselinu prije započinjanja bilo kojeg dugoročnog liječenja.
No carcinogenicity study has been conducted with carglumic acid. 
Studije karcinogenosti nisu provedene s karglumatnom kiselinom.
Uncommon: pyrexia 
Manje često: pireksija
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
Unutar svake skupine učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti
After a single oral dose of 100 mg/kg body weight, approximately 30% of carglumic acid is estimated to be absorbed. 
Nakon pojedinačne oralne doze od 100 mg/kg tjelesne težine, procijenjeno je da se apsorbira oko 30% karglumatne kiseline.
Plasma levels of carglumic acid were measured in patients of all age categories, from newborn infants to adolescents, treated with various daily doses (7 - 122 mg/kg/day). 
Razina karglumatne kiseline u plazmi izmjerena je kod bolesnika svih dobnih skupina, od novorođenčadi do adolescenata, liječenih raznim dnevnim dozama (7 - 122 mg/kg/dan).
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder. 
Za sve infromacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje u promet gotovog lijeka:
Carbaglu treatment should be initiated under the supervision of a physician experienced in the treatment of metabolic disorders. 
Liječenje lijekom Carbaglu treba započeti pod nadzorom liječnika s iskustvom u liječenju poremećaja metabolizma.
Hyperammonaemia may be due to 
Hiperamonijemija se može javiti zbog
The tablets must be dispersed in a minimum of 5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric tube. 
Tablete se moraju otopiti u najmanje 5-10 ml vode i odmah popiti ili primijeniti brzim istiskivanjem štrcaljke kroz nazogastrični tubus.
Plasma levels of ammonia and amino acids should be maintained within normal limits. 
Razine amonijaka i aminokiselina u plazmi se moraju održavati unutar normalnih granica.
If you forget to take Carbaglu Do not take a double dose to make up for forgotten individual doses. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu pojedinačnu dozu.
Uncommon: increased transaminases 
Manje često: povišene vrijednosti transaminaza
- Undesirable effects in organic acidaemia 
- Nuspojave kod organske acidemije
After first opening of the container: do not refrigerate, do not store above 30C. 
Nakon prvog otvaranja spremnika: ne odlagati u hladnjak, ne čuvati na temperaturi iznad 30°C.
Discard 3 months after first opening. 
Lijek zbrinite 3 mjeseca nakon prvog otvaranja.
The following side effects were reported as follows: very common (occurring in at least one in 10 patients), common (occurring in at least one in 100 patients), uncommon (occurring in at least one in1,000 patients), rare (occurring in at least one in 10,000 patients), very rare (occurring in at least one in 100,000 patients) and not known (frequency cannot be estimated from the available data). 
Sljedeće nuspojave prijavljene su kako slijedi: vrlo često (javljaju se kod barem jednog na 10 bolesnika), često (javljaju se kod barem jednog na 100 bolesnika), manje često (javljaju se kod barem jednog na 1 000 bolesnika), rijetko (javljaju se kod barem jednog na 10 000 bolesnika), vrlo rijetko (javljaju se kod barem jednog na 100 000 bolesnika) i nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
Metabolites are detectable in plasma with a peak at 36-48 hours and a very slow decline (half-life around 100 hours). 
Metaboliti se mogu mjeriti u plazmi s vršnom koncentracijom nakon 36-48 sati te vrlo sporim padom (poluvijek oko 100 sati).
When the patient is in hyperammonaemic coma, Carbaglu is administered by fast push through a syringe via the tube set up and used to feed you. 
Kada je bolesnik u stanju hiperamonijačne kome, Carbaglu se primjenjuje brzim potiskivanjem sadržaja unutar štrcaljke kroz postavljenu cijev koja se koristi za hranjenje.
One metabolite that has been identified in the faeces is glutamic acid. 
Jedan metabolit koji je identificiran u stolici je glutaminska kiselina.
Reported adverse reactions are listed below, by system organ class and by frequency. 
Zabilježene nuspojave navedene su niže, prema klasifikaciji organskih sustava i učestalosti.
Breast-feeding during the use of carglumic acid is contraindicated (see sections 4.6 and 5.3). 
Kontraindicirano je dojenje tijekom primjene karglumatne kiseline (vidjeti dio 4.6 i 5.3).
In newborn rats receiving daily carglumic acid by oral gavage for 18 days as well as in young rats receiving daily carglumic acid for 26 weeks, the No Observed Effect Level (NOEL) was established at 500 mg/kg/day and the No Observed Adverse Effect Level (NOAEL) was established at 1000 mg/kg/day. 
Kod novorođenih štakora koji su dnevno primali karglumatnu kiselinu putem oralne cjevčice za hranjenje kroz 18 dana, kao i kod mladih štakora koji su dnevno primali karglumatnu kiselinu kroz 26 tjedana, utvrđena je doza bez uočenog učinka (No Observed Effect Level; NOEL) pri 500 mg/kg/dan te doza bez uočenog štetnog učinka (No Observed Adverse Effect Level; NOAEL) pri 1000 mg/kg/dan.
The initial daily dose should be 100 mg/kg, up to 250 mg/kg if necessary. 
Početna dnevna doza treba biti 100 mg/kg do 250 mg/kg ako je potrebno.
No studies on the effects on the ability to drive and use machines have been performed. 
Nisu provedene specifične studije o učincima na sposobnost upravljanja vozilima i rada na strojevima.
• For isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia: The treatment should start upon hyperammonaemia in organic acidaemia patients. 
• Za izovaleričnu acidemiju, metilmaloničnu acidemiju i propionsku acidemiju: Liječenje je potrebno početi nakon hiperamonijemije u bolesnika s organskom acidemijom.
Carglumic acid is secreted in the milk of lactating rats and although developmental parameters were unaffected, there were some effects on body weight / body weight gain of pups breast-fed by dams treated with 500 mg/kg/day and a higher mortality of pups from dams treated with 2000 mg/kg/day, a dose that caused maternotoxicity. 
Karglumatna kiselina izlučuje se u mlijeku ženki štakora te iako nije utjecala na razvojne parametre, bilo je nekih učinaka na tjelesnu težinu/porast tjelesne težine mladunčadi dojene od majki koje su dobivale 500 mg/kg/dan te povećane smrtnosti mladunčadi majki koje su dobivale 2000/kg/dan, dozu koja je dovodila do toksičnosti u ženki.
- This medicine has been prescribed for you personally and you should not pass it on to others. 
- Ovaj je lijek propisan samo Vama.
Carglumic acid is a structural analogue of N-acetylglutamate, which is the naturally occurring activator of carbamoyl phosphate synthetase, the first enzyme of the urea cycle. 
Karglumatna kiselina je strukturni analog N-acetilglutamata koji je prirodan aktivator karbamoil fosfat sintetaze, prvog enzima u ciklusu ureje.
The plasma elimination curve of carglumic acid is biphasic with a rapid phase over the first 12 hours after administration followed by a slow phase (terminal half life up to 28 hours). 
Krivulja eliminacije karglumatne kiseline iz plazme je bifazična s brzom fazom unutar prvih 12 sati od primjene praćena sporom fazom (poluvijek do 28 sati).
In patients with organic acidaemia (neonates and non-neonates), the treatment with carglumic acid induced a quick decrease of ammonia plasma levels, reducing the risk of neurological complications. 
U bolesnika s organskom acidemijom (novorođenčad i dojenčad) liječenje karglumatnom kiselinom dovelo je do brzog smanjenja razine amonijaka u plazmi, smanjujući rizik pojave neuroloških komplikacija.
Do not use after the expiry date stated on the tablet container. 
Ne smije se upotrijebiti nakon isteka roka valjanosti navedenog na spremniku za tablete.
After first opening of the tablet container: do not refrigerate, do not store above 30C. 
Nakon prvog otvaranja spremnika s tabletama: ne odlagati u hladnjak, ne čuvati na temperaturi iznad 30°C.
In patients with N-acetylglutamate synthase deficiency, carglumic acid was shown to induce a rapid normalisation of plasma ammonia levels, usually within 24 hours. 
Kod bolesnika s deficitom N-acetilglutamat sintaze pokazalo se da karglumatna kiselina dovodi do brze normalizacije razine amonijaka u plazmi, obično unutar 24 sata.